<DOC>
	<DOCNO>NCT03085303</DOCNO>
	<brief_summary>Multicentric , placebo‐controlled , double‐blinded , three‐armed , prospective , randomize control trial.150 patient diagnose atopic dermatitis randomize arm 1 ( irradiation 30min 415nm wavelength ) , arm 2 ( irradiation 30min 450nm wavelength ) , arm 3 ( irradiation 30min low‐dose ( placebo ) ) . Irradiation schedule 3 time week 8 week . Patients follow four week last irradiation .</brief_summary>
	<brief_title>Treatment Atopic Dermatitis Full‐Body Blue Light Device</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Signed date informed consent prior study mandated procedure Good health determine Investigator Willing able comply study requirement Atopic dermatitis ( AD ) fulfilling United Kingdom ( UK ) criteria AD Age 18 ≤ 75 year Reliable method contraception woman childbearing potential ( i.e . low failure rate le 1 % per year ; e.g . oral contraceptive , intrauterine device [ IUD ] transdermal contraceptive patch ) Willing abstain excessive sun / UV exposure ( e.g . sunbathe , solarium ) course study Body Mass Index ≥ 18 ≤ 35 General Inmates psychiatric ward , prison , state institution Investigator team member involve directly indirectly conduct clinical study Participation another clinical trial within last 30 day Pregnant nursing woman Risk noncompliance study procedures Medical History Past present disease , judge investigator , may affect outcome study . These disease may include cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , endocrine disease pulmonary disease , others . Clinically relevant abnormality hematology , blood chemistry screen . Positive HIV1/2Ab , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) test screening . Diastolic blood pressure 95 mmHg . Febrile illness within 2 week prior baseline visit . Alcohol drug abuse within 12 month prior screen ( i.e. , Regular daily consumption 1 liter beer equivalent quantity approximately 40 g alcohol another form . ) Photodermatosis and/or significant photosensitivity , include porphyria and/or hypersensitivity porphyrin well photosensitivity due present past ( within last year ) intake amiodarone . Congenital acquire immunodeficiency Patients diagnose invasive skin cancer time ( =malignant cell invade basal membrane epidermis ) , severe actinic damage present baseline visit . Patients genetic deficiency attach increased sensitivity light increase risk dermatologic cancer ( i.e . Xeroderma pigmentosum , Cockayne Syndrome , BloomSyndrome ) . Concomitant medication/treatment medical history study Within 8 week prior baseline visit : Systemic immunosuppression treatment ( steroid , cyclosporine , azathioprine , Mycophenolate Mofetil ( MMF ) ) Within 4 week prior baseline visit : UV radiation treatment Within 2 week prior baseline visit : Topical steroid treatment Topical calcineurin inhibitor treatment Within 3 day prior baseline visit : Photosensitising medication ( e.g . psoralen , tetracycline , hydrochlorothiazide , phenothiazine , quinolones , hypericumperforatum , arnica , valerian , tar ) assess regular medication plan patient colour ( e.g . thiazide , toluidine blue , eosin , methylene blue , rise Bengal , acridine ) visible patient 's skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>